[1] |
Sung H,Ferlay J,Siegel RL,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin,2021,71(3):209-249.
|
[2] |
Cronin KA,Lake AJ,Scott S,et al. Annual report to the nation on the status of cancer,part I: national cancer statistics[J]. Cancer,2018,124(13):2785-2800.
|
[3] |
张伟,蔡振花. 早期胃癌患者腹腔镜胃癌根治术后复发相关因素分析[J/CD].中华普外科手术学杂志(电子版),2020,14(06):566-568.
|
[4] |
Cao W,Chen HD,Yu YW,et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J(Engl),2021,134(7):783-791.
|
[5] |
Mizrak Kaya D,Nogueras-González GM,Harada K,et al. Risk of peritoneal metastases in patients who had negative peritoneal staging and received therapy for localized gastric adenocarcinoma[J]. J Surg Oncol,2018,117(4):678-684.
|
[6] |
钱金平,吉冬丽. 老年胃癌伴腹膜转移患者预后不良的危险因素及模型建立[J].老年医学与保健,2022,28(03):479-483,492.
|
[7] |
何可,臧洲. T4期胃癌患者行腹腔镜根治术后远期预后的影响因素研究[J/CD].中华普外科手术学杂志(电子版),2021,15(04):404-406.
|
[8] |
Chen S,Chen X,Nie R,et al. A nomogram to predict prog nosis for gastric cancer with peritoneal dissemination[J]. Chin J Cancer Res,2018,30(4):449-459.
|
[9] |
刘宁,卢宁. 外周血中HPR、PLR联合CEA对胃癌的诊断预测价值[J]. 中外医学研究,2022,20(08):74-79.
|
[10] |
刘圣文,张红雨,王华南,等. 胃印戒细胞癌与胃混合印戒细胞癌患者临床病理资料及预后对比分析[J]. 山东医药,2023,63(08):6-10.
|
[11] |
张文静,吴克俭,谭宁平. 早期胃癌淋巴结转移的危险因素及预后分析[J]. 中国中西医结合消化杂志,2020,28(05):331-337.
|
[12] |
刘苗,王英南,张韶辰,等. 影响胃癌根治术后早期复发的危险因素分析[J].临床肿瘤学杂志,2020,25(10):905-910.
|
[13] |
孔维东. 胃癌根治术后早期复发转移的危险因素分析[J]. 保健医学研究与实践,2021,18(S1):262-264.
|
[14] |
李磊,费建东,宋利琴,等. 新辅助化疗结合腹腔镜胃癌根治术治疗进展期胃癌的生存质量及生存率分析[J/CD]. 中华普外科手术学杂志(电子版),2020,14(01):66-69.
|
[15] |
Levenson G,Voron T,Paye F,et al. Tumor downstaging after neoadjuvant chemotherapy determines survival after surgery for gastric adenocarcinoma[J]. Surgery,2021,170(6):1711-1717.
|
[16] |
Zhu L,Xu Y,Shan Y,et al. Intraperitoneal perfusion chemotherapy and whole abdominal hyperthermia using external radiofrequency following radical D2 resection for treatment of advanced gastric cancer[J]. Int J Hyperthermia,2019,36(1):403-407.
|
[17] |
徐晓燕,方乐平,姬玉,等. 胃癌根治术后早期复发的临床病理特点及预后分析[J]. 现代肿瘤医学,2018,26(05):728-733.
|
[18] |
Lui SA,Tan WB,Tai BC,et al. Predictors of survival outcome following radical gastrectomy for gastric cancer[J]. ANZ J Surg,2019,89(1-2):84-89.
|
[19] |
Yang LP,Wang ZX,He MM,et al. A real-world evidence of efficacy of palliative gastrectomy plus chemotherapy in metastatic gastric cancer patients[J]. Cancer Manag Res,2019,11(1):3993-4003.
|
[20] |
Kim DW,Park DG,Song S,et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as treatment options for peritoneal metastasis of advanced gastric cancer[J].J Gastric Cancer,2018,18(3):296-304.
|
[21] |
彭茜,李仕卿,武海涛,等. 肿瘤细胞减灭术联合腹腔热灌注化疗治疗胃癌腹膜转移的远期疗效[J]. 中国临床研究,2020,33(11):1449-1453.
|
[22] |
Hara H,Kadowki S,Asayama M,et al. First-line bolus 5-fluorouracil plus leucovorin for peritoneally disseminated gastric cancer with massive ascites or inadequate oral intake[J]. Int J Clin Oncol,2018,23(2):275-280.
|
[23] |
Ohnuma H,Sato Y,Hirakawa M,et al. Docetaxel,cisplatin and S-1(DCS)combination chemotherapy for gastric cancer patients with peritoneal metastasis: a retrospective study[J]. Cancer Chemother Pharmacol,2018,81(3):539-548.
|
[24] |
丁平安,杨沛刚,田园,等. 腹腔热灌注化疗联合全身系统化疗及阿帕替尼转化治疗对胃癌腹膜转移的疗效[J]. 中国肿瘤临床,2021,48(08):409-414.
|
[25] |
Canbay E,Torun BC,Cosarcan K,et al. Surgery with hyperthermic intraperitoneal chemotherapy after response to induction chemotherapy in patients with peritoneal metastasis of gastric cancer[J]. J Gastrointest Oncol,2021,12(Suppl 1):S47-S56.
|
[26] |
Fuchs CS,Doi T,Jang RW,et al. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial[J]. JAMA Oncol,2018,4(5):e180013.
|
[27] |
Shitara K,Özgüroğlu M,Bang YJ,et al. Pembrolizumab versus paclitaxel for previously treated,advanced gastric or gastro-oesophageal junction cancer(KEYNOTE-061): a randomised,open-label,controlled,phase 3 trial[J]. Lancet,2018,392(10142):123-133.
|
[28] |
王超,蔡建,王辉,等. 胃癌腹膜转移患者经程序性死亡蛋白-1抑制剂治疗出现免疫相关性脑病一例[J]. 中华胃肠外科杂志,2022,25(03):266-268.
|